Clinical Research Directory
Browse clinical research sites, groups, and studies.
Genetics of Response to Canagliflozin
Sponsor: University of Maryland, Baltimore
Summary
Five daily doses of canagliflozin (300 mg) will be administered to healthy volunteers. Pharmacodynamic responses to canagliflozin will be assessed both at 2 days and 6 days after administration of the first dose of canagliflozin. A genome-wide association study (GWAS) will be conducted to search for genetic variants that are associated with each of the pharmacodynamic responses to canagliflozin.
Official title: Pharmacogenomics to Predict Responses to SGLT2 Inhibitors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
700
Start Date
2016-09
Completion Date
2026-12-25
Last Updated
2025-12-18
Healthy Volunteers
Yes
Conditions
Interventions
Canagliflozin
Healthy volunteers will receive canagliflozin (300 mg per day) in the morning for five days.